222 related articles for article (PubMed ID: 10209447)
21. C-myc oncogene expression in ocular melanomas.
Royds JA; Sharrard RM; Parsons MA; Lawry J; Rees R; Cottam D; Wagner B; Rennie IG
Graefes Arch Clin Exp Ophthalmol; 1992; 230(4):366-71. PubMed ID: 1505770
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
Takano Y; Saegusa M; Ikenaga M; Okayasu I
Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
[TBL] [Abstract][Full Text] [Related]
23. Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL).
Palestro G; Ponti R; Chiusa L; Chiarle R; Geuna M; Novero D; Freilone R; Pich A
Eur J Haematol; 1997 Sep; 59(3):148-54. PubMed ID: 9310122
[TBL] [Abstract][Full Text] [Related]
24. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance.
Riva C; Lavieille JP; Reyt E; Brambilla E; Lunardi J; Brambilla C
Eur J Cancer B Oral Oncol; 1995 Nov; 31B(6):384-91. PubMed ID: 8746269
[TBL] [Abstract][Full Text] [Related]
25. Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy.
Brantley MA; Worley L; Harbour JW
Am J Ophthalmol; 2002 Feb; 133(2):242-8. PubMed ID: 11812429
[TBL] [Abstract][Full Text] [Related]
26. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
27. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
28. p53, Bcl-2 and C-Myc expressions in colorectal carcinoma associated with schistosomiasis in Egypt.
Zalata KR; Nasif WA; Ming SC; Lotfy M; Nada NA; El-Hak NG; Leech SH
Cell Oncol; 2005; 27(4):245-53. PubMed ID: 16308474
[TBL] [Abstract][Full Text] [Related]
29. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer.
Schwandner O; Schiedeck TH; Bruch HP; Duchrow M; Windhoevel U; Broll R
Eur J Cancer; 2000 Feb; 36(3):348-56. PubMed ID: 10708936
[TBL] [Abstract][Full Text] [Related]
30. The clinical significance of c-myc oncogene expression in melanomas of the scalp.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 1998 Apr; 51(3):191-4. PubMed ID: 9664877
[TBL] [Abstract][Full Text] [Related]
31. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of c-myc oncogene expression in uveal melanoma.
Chana JS; Cree IA; Foss AJ; Hungerford JL; Wilson GD
Melanoma Res; 1998 Apr; 8(2):139-44. PubMed ID: 9610866
[TBL] [Abstract][Full Text] [Related]
33. Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
Chen Y; Fang L; Zhang J; Li G; Ma M; Li C; Lyu J; Meng QH
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282916
[TBL] [Abstract][Full Text] [Related]
34. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
Pich A; Margaria E; Chiusa L
J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
[TBL] [Abstract][Full Text] [Related]
35. Expression analysis of apoptosis-related markers TP53, BCL-2, BAX and c-MYC in female genital tract sarcomas.
Liu FS; Jan YJ; Lai CR; Twu NF; Lu CH; Hung MJ; Hsieh YT; Chiou LC
J Chin Med Assoc; 2008 Dec; 71(12):628-34. PubMed ID: 19114327
[TBL] [Abstract][Full Text] [Related]
36. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
[TBL] [Abstract][Full Text] [Related]
37. The relation between c-myc expression and interferon sensitivity in uveal melanoma.
Tulley PN; Neale M; Jackson D; Chana JS; Grover R; Cree I; Grobbelaar AO; Wilson GD
Br J Ophthalmol; 2004 Dec; 88(12):1563-7. PubMed ID: 15548813
[TBL] [Abstract][Full Text] [Related]
38. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
Sjöström-Mattson J; Von Boguslawski K; Bengtsson NO; Mjaaland I; Salmenkivi K; Blomqvist C
Acta Oncol; 2009; 48(8):1137-43. PubMed ID: 19863221
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours.
Heidenreich A; Schenkman NS; Sesterhenn IA; Mostofi KF; Moul JW; Srivastava S; Engelmann UH
APMIS; 1998 Jan; 106(1):90-9; discussion 99-100. PubMed ID: 9524567
[TBL] [Abstract][Full Text] [Related]
40. Bcl-2, p53 and c-myc expression in juvenile dermatomyositis.
Falcini F; Calzolari A; Generini S; Pignone A; Simonini G; Zulian F; Matucci-Cerinic M
Clin Exp Rheumatol; 2000; 18(5):643-6. PubMed ID: 11072611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
